Project Grant R01CA307676
Award Date 6/20/26
Completion Date 5/31/31
Dollars Obligated $640K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
- Federal Project Grant Summary The National Cancer Institute (NCI) awarded University of California Irvine $807,372 on March 19, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a systematic genetic screening approach for identifying drug-diet interactions that enhance cancer therapy efficacy. The research focuses on establishing an unbiased, parallel screening platform using syngeneic orthotopic pancreatic ductal adenocarcinoma (PDAC) models to evaluate interactions...
- Federal Grant Award Summary The National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded a $661,721 Project Grant to the University of California, San Diego, effective April 1, 2026, through March 31, 2031. This award supports systematic functional mapping and interrogation of oncogenic intrinsically disordered regions (IDRs) in cancer driver proteins. The research will utilize high-throughput functional screening technologies to perform domain and residue-level...
- Federal Grant Award Summary The University of California, Irvine received a $138,489 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded on September 20, 2025, with a completion date of September 19, 2027. The award supports research and development of a methyl arginine targeting chimera (MARTAc) for the lysosomal degradation of intracellular proteins. This project addresses critical limitations of current proteolysis-targeting...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant of $648,626 to the University of California, Irvine, effective April 2, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award supports research investigating the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI), specifically how programmed death receptor 1 (PD-1) blockade affects tumor microenvironments. The research seeks to...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $463,279 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 1, 2026 through June 30, 2031. The award supports research investigating ubiquitin-specific peptidase 1 (USP1) inhibition as a therapeutic strategy to overcome PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOC) patients harboring homologous recombination (HR)...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $673,522 Project Grant, effective July 1, 2026 through June 30, 2031, under the Cancer Cause and Prevention Research program (CFDA 93.393). Under the direction of Principal Investigator Dr. Orlando Schärer, this award funds comprehensive research into the dynamic mechanisms of nucleotide excision repair (NER), the primary cellular pathway responsible for removing DNA lesions caused by solar...
- Federal Project Grant Summary The National Cancer Institute awarded the University of California, Los Angeles a $649,181 Project Grant on August 8, 2025, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop advanced chemoproteomics technologies for covalent drug target discovery. The grant funds the establishment of high-throughput multidimensional chemoproteomics platforms designed to identify and characterize cysteine residues in cellular proteins that can be...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Southern California $479,234 on May 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate nonsense-mediated mRNA decay (NMD) mechanisms in cancer. The project, which extends through April 30, 2031, will deliver fundamental research elucidating NMD's regulatory role in cancer biology beyond its conventional function of degrading faulty mRNA transcripts. The research encompasses three...
- Federal Grant Award Summary The National Cancer Institute awarded UC San Diego a $771,811 Project Grant (CFDA 93.395: Cancer Treatment Research) effective June 1, 2026, through May 31, 2029, to identify small molecule activators of Type I Interferon (IFN-I) signaling for cancer treatment. The research project addresses a critical gap in cancer immunotherapy by developing inhibitors targeting USP18, a ubiquitin protease that negatively regulates IFN-I feedback signaling. Current clinical...